Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferasirox - Austhera Biosciences

Next Previous
Drug Profile

Deferasirox - Austhera Biosciences

Alternative Names: AST-0509; DST-0509; K-DFX

Latest Information Update: 26 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DisperSol Technologies
  • Developer AustinPx
  • Class Antianaemics; Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Iron overload

Most Recent Events

  • 16 Aug 2021 DisperSol Technologies completes a phase-II trial in Iron overload (Treatment-experienced, In children, In adolescents, In adults, In the elderly) in Thailand (PO) (NCT03637556)
  • 10 Mar 2021 Deferasirox licensed to Austhera Biosciences prior to March 2021 (Austhera Biosciences pipeline, March 2021)
  • 10 Mar 2021 DisperSol Technologies plans a phase III trial for Iron overload in 2021 (DisperSol Technologies pipeline, March 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top